Format

Send to

Choose Destination
Eur Respir Rev. 2017 Jun 28;26(144). pii: 160110. doi: 10.1183/16000617.0110-2016. Print 2017 Jun 30.

Diet and exercise in the management of obstructive sleep apnoea and cardiovascular disease risk.

Author information

1
Dept of Kinesiology, Towson University, Towson, MD, USA ddobrosielski@towson.edu.
2
Both authors contributed equally.
3
Human Nutrition Dept, Hospital Universitari Sant Joan, Institut d'Investigació Sanitaria Pere Virgili, Universitat Rovira i Virgili, Reus, Spain.
4
Dept of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.
5
Ciber Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.

Abstract

Obstructive sleep apnoea (OSA) is associated with increased cardiovascular disease (CVD) morbidity and mortality. It is accepted that OSA and obesity commonly coexist. The American Academy of Sleep Medicine recommends dietary-induced weight loss and exercise as lifestyle treatment options for OSA. However, most clinical trials upon which this recommendation is based have focused on establishing the effectiveness of calorie-restricted, often low-fat diets for improving OSA severity, whereas less attention has been given to the means through which weight loss is achieved (e.g. altered dietary quality) or whether diet or exercise mediates the associations between reduced weight, improved OSA severity and the CVD substrate. The current evidence suggests that the benefits of a low-carbohydrate or Mediterranean diet in overweight and obese individuals go beyond the recognised benefits of weight reduction. In addition, exercise has an independent protective effect on vascular health, which may counter the increased oxidative stress, inflammation and sympathetic activation that occur in OSA patients. This review aims to expand our understanding of the effects of diet and exercise on OSA and associated CVD complications, and sets the stage for continued research designed to explore optimal lifestyle strategies for reducing the CVD burden in OSA patients.

PMID:
28659501
PMCID:
PMC5559698
DOI:
10.1183/16000617.0110-2016
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center